Rubraca
Description
Rubraca is a cancer medicine for treating high-grade cancers of the ovary, fallopian tubes (the tubes connecting the ovaries to the uterus) and the peritoneum (the membrane lining the abdomen). It is used as maintenance treatment in patients newly diagnosed with advanced cancer or in patients whose cancer has come back, and in whom the cancer has cleared (partially or completely) after treatment with platinum-based chemotherapy. The active substance in Rubraca, rucaparib, blocks the activity of a family of proteins called poly(ADP-ribose) polymerases (PARPs) that help to repair damaged DNA in cells (both normal and cancer cells). When PARP proteins are blocked, the damaged DNA in the cancer cells cannot be repaired and the cells die as a result.
Qualitative and quantitative composition
Rubraca 200 mg film-coated tablets Each tablet contains rucaparib camsylate corresponding to 200 mg rucaparib. Rubraca 250 mg film-coated tablets Each tablet contains rucaparib camsylate corresponding to 250 mg rucaparib. Rubraca 300 mg film-coated tablets Each tablet contains rucaparib camsylate corresponding to 300 mg rucaparib.
Pharmaceutical form
Film-coated tablet.
Rubraca 200 mg film-coated tablet Blue, 11 mm, round f ilm-coated tablet, debossed with “C2”.
Rubraca 250 mg film-coated tablet White, 11 × 15 mm, diamond-shaped film-coated tablet, debossed with “C25”.
Rubraca 300 mg film-coated tablet Yellow, 8 × 16 mm, oval film-coated tablet, debossed with “C3”.
SE: https://www.fass.se/LIF/startpage
NO: https://www.felleskatalogen.no
DK: http://www.produktresume.dk
FI: https://www.fimea.fi
EU: https://www.ema.europa.eu/
